Delving into the Latest Updates on Leuprolide Acetate with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Leuprolide acetate (USP), Leuprorelin Acetate, Leuprorelin acetate (JP17)

+ [30]

Target

GnRHR

Mechanism

GnRHR agonists(Gonadotropin-releasing hormone receptor agonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesCongenital Disorders+ [4]

Active Indication

Bulbo-Spinal Atrophy, X-LinkedAdvanced Prostate CarcinomaUterine Neoplasms+ [9]

Inactive Indication

Choroid Plexus Papilloma

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

TOLMAR, Inc.

Takeda Pharmaceutical Co., Ltd.

Daewoong Pharmaceutical Co., Ltd.

+ [4]

Inactive Organization

Ortho-McNeil Pharmaceutical LLC

AbbVie, Inc.

Drug Highest PhaseApproved

First Approval Date

US (09 Apr 1985),

Advanced Prostate Carcinoma

RegulationOrphan Drug (US)

Login to view First Approval Timeline

Structure

Molecular FormulaC59H84N16O12.C2H4O2

InChIKeyRGLRXNKKBLIBQS-XNHQSDQCSA-N

CAS Registry74381-53-6

Gene Sequence

Sequence Code 20294387

This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other places is the body (metastatic). Bipolar androgen therapy is the regulation of testosterone between castration levels (lower than what would be normally present) and supraphysiological levels (amounts greater than normally found in the body). This may suppress cancer cell growth, which reduces prostate-specific antigen (PSA) levels and may delay cancer progression.

Start Date01 Jun 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

NCT06397703 / RecruitingPhase 3

A Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy And Ultra-Hypofractionated SBRT Versus Ultra-Hypofractionated SBRT Alone For Unfavorable Intermediate Risk Prostate Cancer

For this proposed Phase III study, unfavorable intermediate risk prostate cancer patients will be randomized to receive 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic body radiation therapy/radiosurgery (SBRT) directed to the prostate versus SBRT alone. The patient population will include those with National Comprehensive Cancer Network (NCCN)-defined unfavorable intermediate risk disease. All patients will be followed every 6 months for up to 5 years from the first patient randomized and will undergo a routine 24-30 months post-SBRT prostate biopsy to assess for local tumor control.

Start Date16 Apr 2024

Sponsor / Collaborator

NYU Langone Health

NCT06330805 / Not yet recruitingPhase 2

A Comparison of Orgovyx (Relugolix) vs Eligard (Leuprolide) on Cardiovascular Function and Biomarkers During Standard of Care Combined ADT (Androgen Deprivation Therapy)-Radiation for Prostate Cancer

This phase II trial compares the effect of relugolix to leuprolide on cardiac function and performance in patients with prostate cancer. Androgen deprivation therapy (ADT) has been a key component for the treatment of advanced prostate cancer for decades. The term androgen deprivation therapy means lowering a man's testosterone. Long-term studies show that ADT may contribute to a detriment to cardiac health and predisposes men to developing cardiac diseases. Recent studies suggest that men taking relugolix for treatment of prostate cancer may have a lower risk of developing cardiovascular problems, but more studies are needed to understand this observation, and there are currently no studies reporting the direct impact of ADT (relugolix, versus the more-commonly used leuprolide) on cardiac function and outcomes.
Participants will receive definitive radiotherapy for unfavorable intermediate risk prostate cancer and 6-month ADT (either relugolix or leuprolide). In addition, participants will undergo the following:
1. Comprehensive cardiac and exercise testing before and after starting ADT
2. Completion of quality-of-life questionnaires at specific intervals during the study period
3. Provide blood samples at specific intervals during the study period to test for changes in steroid levels and certain biomarkers

Start Date01 Apr 2024

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+3]

100 Clinical Results associated with Leuprolide Acetate

Login to view more data

100 Translational Medicine associated with Leuprolide Acetate

Login to view more data

100 Patents (Medical) associated with Leuprolide Acetate

Login to view more data

1,592

Literatures (Medical) associated with Leuprolide Acetate

01 Feb 2024·Journal of Pharmacy Practice

Hormonal Therapy in Pretreated Patients With Recurrent Ovary Granulosa Cell Tumor

Article

Author: Topuz, Samet ; Aydin, Esra ; Dogan, Izzet ; Aydiner, Adnan ; Saip, Pinar ; Salihoglu, Mehmet Y.

Objective: To evaluate the effectiveness of hormonal therapy (HT) in patients with recurrent adult ovary granulosa cell tumors. Methods: The clinical and treatments features of the patients who received HT were studied retrospectively. The efficacy and safety of HT were evaluated. The Kaplan-Meier technique was used to conduct survival analysis. Results: The research involved a total of thirteen patients. The median age of the participants was 49 years (range: 34-61). Since diagnosis, the median number of surgeries has been three (range: 2-8). At least one chemotherapy regimen has been administered to 12 (92.3%) patients. Ten of the patients (76.9%) had at least two metastatic areas. Lung metastases were found in two (15.4%) of the patients. Inhibin B levels were elevated in 81.2% of patients before hormone treatment. The patients received different HTs (Leuprolide acetate + anastrozole-three patients, leuprolide acetate + tamoxifen-six patients, only anastrozole-three patients, only tamoxifen-one patients). The median progression-free survival was found 17.7 months (95 % CI: 14.7-20.6). In four (33.4%) patients, an overall response (complete or partial) was identified. A stable response was observed in eight (66.7%) patients. Conclusions: HT is effective in pretreated individuals with recurrent ovarian granulosa cell tumors, according to this research. Despite the limited number of patients and treatment variability, disease control was achieved in all patients. Also, we found that Inhibin B levels were associated with treatment response.

29 Jan 2024·Journal of Pediatric Endocrinology and Metabolism

Efficacy and safety of leuprorelin 3-month depot (11.25 mg) for idiopathic central precocious puberty treatment of Chinese girls: a single-center retrospective study

Article

Author: Liu, Zulin ; Ou, Hui ; Huang, Siqi ; Gao, Chenchen ; Wang, Dilong ; Liang, Liyang ; Meng, Zhe ; Hou, Lele ; Zhang, Lina ; Xu, Yingying

Abstract:

Objectives:

This study aimed to evaluate the efficacy and safety of 3-month leuprorelin acetate (3-month LA, 11.25 mg) for the treatment of idiopathic central precocious puberty (ICPP) in Chinese girls.

Methods:

We conducted a single-center retrospective study in China on 28 girls with ICPP who received at least one year of 3-month LA treatment. Data from anthropometry, biochemistry, bone age (BA), and pelvic ultrasonography were assessed before and every 6 months during medication.

Results:

At CPP diagnosis, the mean chronological age (CA) was 7.8±0.8 years, with bone age advancement (BA–CA) of 1.5±0.8 years. After treatment initiation, growth velocity decreased significantly from 8.5±1.6 cm/year to 5.8±1.1 cm/year at month 12 (p<0.001). GnRH-stimulated peak LH ≤3IU/L, the primary efficacy criterion, was observed in 27 out of 28 (96.4 %) children at month 3. Basal estradiol <20 pg/mL was achieved by all 28 girls (100 %) at month 6 and remained stable at month 12. Basal follicle-stimulating hormone (FSH) decreased from 4.1±3.5 to 1.7±0.9 (p<0.001), and basal LH was also significantly reduced from 3.3±6.5 to 0.7±0.8 (p=0.035) at month 12. The mean predicted adult height (PAH) at treatment initiation was 152.7±5.8 cm, it increased significantly to 157.5±5.5 cm (p=0.007) after one-year treatment. Pubertal development was slowed in most patients, and in some cases, it was even reversed. Only one patient (3.6 %) reported local intolerance.

Conclusions:

Three-month leuprorelin acetate is a safe and effective treatment for suppressing the pituitary–gonadal axis and restoring impaired adult height in Chinese girls.

15 Dec 2023·Medicine

Scalp nodules as the first presentation of prostate cancer: A CARE-compliant article

Article

Author: Kim, Hun Soo ; Park, Seung Chol ; Oh, Tae Hoon

Rationale::

Bones are the most common site of prostate cancer metastasis. Other common sites of metastases include the distant lymph nodes, liver, thorax, brain, and digestive system. However, cutaneous metastases from prostate cancer are extremely rare.

Patient concerns::

We present a case of a 61-year-old man with scalp nodules without any cancer history.

Diagnosis::

The patient was diagnosed with metastatic prostate adenocarcinoma through an incisional biopsy for his scalp nodules. The patient presented with a serum prostate-specific antigen level of 10.2 ng/mL; imaging examinations revealed extraprostatic extension, lymph node involvement, and multiple bone metastases.

Intervention::

The patient was treated with androgen deprivation therapy with leuprolide acetate (7.5 mg every month) and abiraterone acetate (1000 mg daily).

Outcomes::

The scalp metastases resolved without adverse effects, and the serum prostate-specific antigen level decreased to 0.02 ng/mL.

Lessons::

Cutaneous metastasis, especially scalp metastasis from prostate cancer, is extremely rare. If there is a rash or nodule on the skin, it is necessary to evaluate it carefully and to confirm it through a biopsy.

38

News (Medical) associated with Leuprolide Acetate

13 May 2024

·www.prnewswire.com

Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting

16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers. Tadaaki Taniguchi, MD, PhD, Chief Medical Officer, Astellas "The data at ASCO demonstrate the strength and breadth of our growing oncology portfolio and provide new insights into our transformative therapies for patients living with some of the most devastating cancers. Recent regulatory achievements mean our oncology medicines are reaching more patients than ever worldwide, and we are continuing to pursue novel targets and invest in research to improve overall survival and raise quality of life." Highlights at the 2024 ASCO Annual Meeting include: Further data from the Phase 3 EV-302 trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), including data in cisplatin-eligible and cisplatin-ineligible populations. These results support the combination as a landmark advancement in the care of patients with la/mUC, regardless of cisplatin eligibility, and serve as the basis of ongoing regulatory reviews by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), Japan's Ministry of Health, Labour and Welfare (MHLW), and the China National Medical Products Administration (NMPA). Final overall survival (OS) results from the Phase 3 SPOTLIGHT study, evaluating the efficacy and safety of zolbetuximab – a first-in-class claudin (CLDN) 18.2-targeted monoclonal antibody approved by Japan's MLHW and currently in review by multiple regulatory authorities for approval worldwide. In this abstract, zolbetuximab is evaluated in combination with mFOLFOX6 (a combination chemotherapy regimen that includes oxaliplatin, leucovorin, and fluorouracil) for the first-line treatment of patients with CLDN18.2 positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. These results underpin the strength of the zolbetuximab clinical data supporting the pursuit of regulatory approvals worldwide. Two new post-hoc analyses of the Phase 3 EMBARK trial, which evaluated enzalutamide plus leuprolide, placebo plus leuprolide, and enzalutamide (single agent) in patients with nonmetastatic hormone- (or castration-) sensitive prostate cancer (nmHSPC or nmCSPC) with high-risk biochemical recurrence (BCR), including an oral presentation on the impact of treatment suspension on health-related quality of life and a poster presentation on sexual activity patient-reported outcomes. Astellas Presentations at 2024 ASCO Annual Meeting About PADCEV and the Astellas, Pfizer and Merck Collaboration Astellas and Pfizer have a clinical collaboration agreement with Merck to evaluate the combination of Astellas' and Pfizer's PADCEV™ (enfortumab vedotin-ejfv) and Merck's KEYTRUDA® (pembrolizumab) in patients with previously untreated metastatic urothelial cancer. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). About XTANDI and the Pfizer/Astellas Collaboration In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE:PFE), and Astellas (TSE: 4503) entered into a commercial agreement to jointly develop and commercialize XTANDI® (enzalutamide) in the United States, while Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing the product outside the United States. Pfizer receives alliance revenues as a share of U.S. profits and receives royalties on sales outside the U.S. About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at . Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. The safety and efficacy of the agent(s) under investigation have not been established for the use(s) being considered. There is no guarantee that the agent(s) will receive regulatory approval and become commercially available for the use(s) being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. SOURCE Astellas Pharma Inc.

Phase 3License out/inDrug ApprovalASCO

24 Apr 2024

·firstwordpharma.com

Astellas’ Xtandi wins EU nod for earlier use in prostate cancer

The European Commission greenlit Astellas’ Xtandi (enzalutamide) with or without androgen deprivation therapy (ADT) for treating patients with high-risk biochemical recurrence (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) ineligible for salvage radiotherapy.The clearance announced Tuesday comes close on the heels of a favourable opinion adopted by the European Medicines Agency's (EMA) drug advisory body last month. “This expanded approval for Xtandi is a vitally important advance for patients with nmHSPC with high-risk BCR,” positioning it “as a new option for treatment in the early…setting,” said Ahsan Arozullah, head of oncology development at Astellas. The timing of the decision also coincides with the recently revised European Association of Urology (EAU) guidelines recommending Xtandi alone or with ADT as a new standard-of-care in this setting, following radiotherapy or surgery.The approval was backed by findings from the Phase III EMBARK study, which involved 1068 patients. Results showed that treatment with Xtandi plus leuprolide led to a significant 58% reduction in the risk of metastasis or death compared with leuprolide alone. The risk reduction was 37% in patients receiving Xtandi monotherapy.Xtandi, co-marketed by Pfizer in the US, secured FDA approval for the same indication in November and has previously been authorised for treating metastatic hormone-sensitive prostate cancer, as well as metastatic and non-metastatic castration-resistant prostate cancer.

Phase 3Clinical ResultDrug Approval

24 Apr 2024

·www.outsourcing-pharma.com

European Commission approves Astellas’ drug for expanded prostate cancer Treatment

“The extended approval allows enzalutamide to be administered either as monotherapy or in combination with androgen deprivation therapy (ADT) for adult men with high-risk biochemical recurrent (BCR) nmHSPC who are unsuitable for salvage-radiotherapy,” said president and CEO of Astellas, Naoki Okamura. “This approval is based on results from the phase 3 Embark trial in 1,068 men with high-risk BCR nmHSPC,” Okamura continued. “The study demonstrated that patients treated with enzalutamide in combination with leuprolide had a 57.6% lower chance of cancer spreading or death compared to those treated with leuprolide alone. Participants receiving enzalutamide alone experienced a 36.9% reduction in risk.” Prostate cancer can lead to metastasis Dr Antonio Alcaraz, chairman of the department of urology at the University Hospital Clinic of Barcelona said that when non-metastatic hormone-sensitive prostate cancer recurs and is allowed to evolve, it could potentially lead to metastasis. He said: “Facing a particularly high risk and poorer outcomes in this stage of prostate cancer are men with a rapidly rising PSA, where PSA levels double within 9 months. It is critical to manage the cancer carefully then, and I urge clinicians not to delay treatment in this setting.” Ernst-Günther Carl, chairman of Europa Uomo, expressed the urgent need for effective treatments for advanced prostate cancer. “Many men with hormone-sensitive prostate cancer undergo arduous surgery and rounds of radiotherapy, which can be a successful way to keep their cancer at bay,” he said. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “It is devastating then when up to four in ten of those will go on to develop a recurrence that puts them at significantly greater risk of their cancer spreading and early death.” Potential new prostate cancer treatment Ahsan Arozullah, senior vice president and head of the oncology department at Astellas said this expanded approval is a vitally important advance for patients with nmHSPC with high-risk BCR. He said: “Efficacy and safety results from the Embark study demonstrate the potential for enzalutamide as a new option for treatment in the early, recurrent hormone-sensitive prostate cancer setting. Astellas is in active discussions with regulatory authorities around the world to bring enzalutamide to those who may benefit.” The EC's approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in March 2024, recommending enzalutamide for high-risk BCR nmHSPC. Enzalutamide was previously approved by the US Food and Drug Administration (FDA) for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with BCR at high risk for metastasis in November 2023. Astellas anticipates reflecting the impact of this approval in its financial forecast for the fiscal year ending March 31, 2025, scheduled for disclosure on April 25, 2024.

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Leuprolide Acetate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00989	Leuprolide Acetate	L02AE02	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bulbo-Spinal Atrophy, X-Linked	JP	Takeda Pharmaceutical Co., Ltd.	28 Aug 2017
Uterine Neoplasms	CN	Takeda Pharmaceutical Co., Ltd.	15 Mar 2000
Breast Cancer	JP	Takeda Pharmaceutical Co., Ltd.	09 Oct 1996
Uterine Fibroids	JP	Takeda Pharmaceutical Co., Ltd.	09 Oct 1996
Puberty, Precocious	US	AbbVie Endocrine, Inc.	16 Apr 1993
Prostatic Cancer	JP	Takeda Pharmaceutical Co., Ltd.	03 Jul 1992
Endometriosis	US	AbbVie Endocrine, Inc.	22 Oct 1990
Leiomyoma	US	AbbVie Endocrine, Inc.	22 Oct 1990
Advanced Prostate Carcinoma	US	AbbVie Endocrine, Inc.	09 Apr 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2-negative breast cancer	Phase 3	US	TOLMAR, Inc.	28 Dec 2022
HER2-negative breast cancer	Phase 3	PR	TOLMAR, Inc.	28 Dec 2022
Choroid Plexus Papilloma	Phase 3	US	AbbVie, Inc.	01 Dec 2008
Alzheimer Disease	Phase 2	US	National Institute on Aging	27 Nov 2020
Mild cognitive disorder	Phase 2	US	National Institute on Aging	27 Nov 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03572387 (CTgov)	Phase 2	Castration-Resistant Prostatic Cancer \| Prostatic Cancer	14	ATRA+5-AZA ('Early' 5-AZA+ATRA)	nyndpfbdmr(gygsnkijof) = xmdeqidppb kdbqxiqvvv (ldherdjyre, ekgncmrxsr - kwvqnmeiub) View more	-	30 Apr 2024
				ATRA+5-AZA ('Delayed' 5-AZA+ATRA)	nyndpfbdmr(gygsnkijof) = eroztilxdn kdbqxiqvvv (ldherdjyre, zexjplaybf - epdvdqxehc) View more
NCT03902951 (SATURN, ASCO_GU2024) Manual	Phase 2	Prostatic cancer metastatic	28	leuprolide+abiraterone acetate+ prednisone+ apalutamide+ SBRT	ymjltulode(tsupokzoix) = tnvxmpcuig gsysrgbbgs (iydmknvytd, 32 ~ 67) View more	Positive	25 Jan 2024
NCT01674140 (CTgov)	Phase 3	Hormone receptor positive HER2 negative breast cancer	1,939	placebo+letrozole+tamoxifen citrate+exemestane+leuprolide acetate+goserelin acetate+anastrozole (Placebo)	nkvrynaqrr(okbrqxpqst) = zoanjxsfzk yvojvelpwn (xfalvgidkz, ndgvurpczg - oxehcbjwsa) View more	-	20 Dec 2023
				Everolimus (Everolimus)	nkvrynaqrr(okbrqxpqst) = mjulobbfwl yvojvelpwn (xfalvgidkz, ktovzhdmdi - xmccmwrasn) View more
ESPE2023	Not Applicable	Puberty, Precocious	582	Leuprolide acetate 11.25mg 3-month formulation	ntnzvjqnom(rxlztbqaoa) = indlimjqko vaabehzayr (owgihbfeqa, 2.27–9.87) View more	-	21 Sep 2023
ESPE2023	Not Applicable	Puberty, Precocious \| Familial Hypophosphatemic Rickets	-	Leuprolide acetate	goaviskxsw(pnykbgaleh) = xquymvlzqk lzsnshhicu (pjjfnspfkf ) View more	Positive	21 Sep 2023
				Burosumab	goaviskxsw(pnykbgaleh) = kknbnwcmxd lzsnshhicu (pjjfnspfkf ) View more
NCT04051320 (CTgov)	Phase 2	Depression, Postpartum \| Irritable Mood \| Depressive Disorder	23	Micronized progesterone+Leuprolide Acetate 3.75 MG/ML+Estradiol 2 Mg tablet (Hormone Sensitive Women (HS+))	gzpamwryhh(rupduxvkea): F statistic = 2.164, P-Value = 0.160 View more	-	25 Aug 2023
				Micronized progesterone+Leuprolide Acetate 3.75 MG/ML+Estradiol 2 Mg tablet (Hormone Insensitive Women (HS-))
NCT03695237 (CTgov)	Phase 3	Puberty, Precocious	45	Leuprolide Acetate (Leuprolide Acetate - Previously Treated)	loqymcirra(ptkhznxthc) = xfoqtvmymn jxrvaonzwh (ifcipeimwf, ntpqahsmom - yahnhivgpx) View more	-	16 May 2023
				Leuprolide Acetate (Leuprolide Acetate - Treament Naïve)	loqymcirra(ptkhznxthc) = dcggcrpiqv jxrvaonzwh (ifcipeimwf, wpmpalyyoz - zrfwiwodoq) View more
NCT02058706 (CTgov)	Phase 2	Adenocarcinoma of prostate \| Metastatic castration-resistant prostate cancer \| Recurrent Prostate Carcinoma	71	orchiectomy+enzalutamide+leuprolide acetate+goserelin acetate (Arm A (Enzalutamide and LHRH Analogue Therapy))	oshaavpycf(ymozlpeokl) = ubqrykzmax gjhfrjtoub (murdptrkvu, fthdyshufb - hxxglvpwee) View more	-	10 May 2023
				orchiectomy+bicalutamide+leuprolide acetate+goserelin acetate (Arm B (Bicalutamide and LHRH Analogue Therapy))	oshaavpycf(ymozlpeokl) = wfvbhtbggo gjhfrjtoub (murdptrkvu, myknlznapz - jzwmboivgc) View more
NCT02990845 (AACR2023) Manual	Phase 2	ER-positive/HER2-negative Breast Cancer First line ER Positive \| HER2 Negative	14	Pembrolizumab+Exemestane+Leuprolide	iyrnillmmi(jlsjvpjblr) = sicnpjmlnv curqzgeauz (xyqzktmnrj ) View more	Positive	14 Apr 2023
NCT03043807 (CTgov)	Phase 2	Oligometastatic Prostate Carcinoma	26	Radiation+Abiraterone Acetate+Docetaxel+Bicalutamide+Leuprolide Acetate	wcygiowftk(ssbucdjakm) = zftazvpmqb robdogqfhf (gncravbdry, hmlpxyflfc - iauntojusn) View more	-	16 Feb 2023